Collegium Pharmaceutical Inc (COLL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Collegium Pharmaceutical Inc (COLL) has a cash flow conversion efficiency ratio of 0.285x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($78.44 Million) by net assets ($274.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see COLL market cap overview for the company's overall valuation and market capitalisation.
Collegium Pharmaceutical Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Collegium Pharmaceutical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Collegium Pharmaceutical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Collegium Pharmaceutical Inc ranked by their cash flow conversion efficiency. Explore Collegium Pharmaceutical Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhang Xiaoquan Inc.
SHE:301055
|
N/A |
|
United States Antimony Corporation
NYSE:UAMY
|
-0.091x |
|
Jiangxi Sanxin Medtec Co Ltd
SHE:300453
|
0.085x |
|
Thesis Gold Inc
V:TAU
|
-0.019x |
|
Xuchang Yuandong Drive Shaft Co Ltd
SHE:002406
|
0.015x |
|
Bringspring Science and Tech
SHE:300290
|
0.019x |
|
Kim Loong Resources Bhd
KLSE:5027
|
0.060x |
|
ST Barbara Ltd
AU:SBM
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Collegium Pharmaceutical Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Collegium Pharmaceutical Inc from 2013 to 2024. View COLL share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $228.84 Million | $204.98 Million | 0.896x | -36.29% |
| 2023-12-31 | $195.43 Million | $274.75 Million | 1.406x | +120.50% |
| 2022-12-31 | $194.84 Million | $124.23 Million | 0.638x | +24.94% |
| 2021-12-31 | $202.93 Million | $103.56 Million | 0.510x | +1.06% |
| 2020-12-31 | $186.03 Million | $93.94 Million | 0.505x | +58.92% |
| 2019-12-31 | $87.43 Million | $27.78 Million | 0.318x | -82.82% |
| 2018-12-31 | $91.58 Million | $169.39 Million | 1.850x | +387.24% |
| 2017-12-31 | $104.08 Million | $-67.02 Million | -0.644x | -15.74% |
| 2016-12-31 | $134.91 Million | $-75.05 Million | -0.556x | -119.45% |
| 2015-12-31 | $85.07 Million | $-21.57 Million | -0.254x | -117.29% |
| 2014-12-31 | $-12.24 Million | $-17.95 Million | 1.466x | +149.51% |
| 2013-12-31 | $5.58 Million | $-16.53 Million | -2.961x | -- |
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more